Health
Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction – News-Medical.Net
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction. That’s the finding of the EMPEROR-Reduced trial presented in a Hot Line session today at ESC Congress 2020.
The EMPEROR-Reduced trial was designed to evaluate the effects of empagliflozin 10 mg once daily (as compared with placebo) in patients with heart failure and a reduced ejection fraction, with or without diabetes, who were already rece…
-
General13 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News16 hours agoSanta drops in for carols
-
General18 hours agoCritically endangered orchid thrives as NSW Mid North Coast cemetery provides habitat refuge
-
Business18 hours agoThe best Australian stock you’ve never heard of